In summary, HDAC inhibitors have been used with varying degrees of success in vitro, in vivo, and in clinical settings to treat cancer, neurodegenerative diseases, and immune disorders, and even as combinatorial approaches for antiviral therapy. Here, HDAC9 is linked to neurodegenerative disease.